Summit Pharmaceuticals International Corporation

9 articles about Summit Pharmaceuticals International Corporation

• Signing of Exclusive Distributorship Agreement With EVERZOM

  6/2/2023

  Summit Pharmaceuticals International has signed an exclusive distributorship agreement in Japan with EVERZOM, SAS*., a France-based company providing exosome manufacturing service.

• CytoReason and Summit Pharmaceuticals International Announce the Introduction of an AI Platform to One of Japan's Top Pharmaceutical Companies

  9/30/2021

  CytoReason and Summit Pharmaceuticals International announced that CytoReason has entered the Japanese market, with its technology being utilized by one of Japan's top pharmaceutical companies.

• Rentschler Biopharma Announces Enhanced Collaboration with Summit Pharmaceuticals International Corporation to Expand Japanese Operation-Base

  10/4/2019

  Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama

• School Bathroom Anxiety a Common and Misunderstood Problem: DocuSol® Kids Offers Help

  8/1/2019

  Despite having completed potty training, many parents find that bathroom issues can continue to persist in their school-age children.

• Constipation Can Spoil Even the Best Vacation. DocuSol® Products Are Developed to Help FAST!

  5/1/2019

  With vacations around the corner, we all know that vacations are an especially difficult time to experience constipation, as individuals find themselves away from home, their doctors, and their pharmacies.

• DocuSol® Kids Mini-Enemas Used for Constipation Related to Childhood Bathroom Avoidance

  4/4/2019

  DocuSol® Kids mini-enemas are often used by parents dealing with children who routinely avoid using the bathroom and become constipated.

• MR Solutions Ltd. Partners With Summit Pharmaceuticals International Corporation To Bring Preclinical Imaging To Japan

  12/1/2015

• NeuralStem Inc. and Summit Pharmaceuticals International Corporation Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan

  6/7/2011

• BioTime Announces A Phase II Clinical Trial Of Hextend(R) In Japan

  12/7/2006